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Abstract: Probiotics have been linked to a reduction in the incidence of necrotizing enterocolitis
and late-onset sepsis in preterm infants. Recently, probiotics have also proved to reduce time to
achieve full enteral feeding (FEF). However, the relationship between FEF achievement and type of
feeding in infants treated with probiotics has not been explored yet. The aim of this systematic
review and meta-analysis was to evaluate the effect of probiotics in reducing time to achieve
FEF in preterm infants, according to type of feeding (exclusive human milk (HM) vs. formula).
Randomized-controlled trials involving preterm infants receiving probiotics, and reporting on time
to reach FEF were included in the systematic review. Trials reporting on outcome according to
type of feeding (exclusive HM vs. formula) were included in the meta-analysis. Fixed-effect or
random-effects models were used as appropriate. Results were expressed as mean difference (MD)
with 95% confidence interval (CI). Twenty-five studies were included in the systematic review. In the
five studies recruiting exclusively HM-fed preterm infants, those treated with probiotics reached FEF
approximately 3 days before controls (MD ´3.15 days (95% CI ´5.25/´1.05), p = 0.003). None of
the two studies reporting on exclusively formula-fed infants showed any difference between infants
receiving probiotics and controls in terms of FEF achievement. The limited number of included
studies did not allow testing for other subgroup differences between HM and formula-fed infants.
However, if confirmed in further studies, the 3-days reduction in time to achieve FEF in exclusively
HM-fed preterm infants might have significant implications for their clinical management.
Keywords: probiotics; preterm infants; human milk; full enteral feeding; systematic review
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1. Introduction
Nutrition during critical time windows in early life can affect long-term health [1]. Early provision
of optimal enteral nutrition to preterm infants might improve neurodevelopmental outcome
by decreasing the rate of several complications of prematurity, such as extrauterine growth
restriction, necrotizing enterocolitis (NEC), sepsis, bronchopulmonary dysplasia, and retinopathy of
prematurity [2].
Late introduction and slow advancement of enteral feeding may alter gastrointestinal motility
and disrupt microbial colonization [3], leading to a delay in establishing full enteral feeding (FEF).
The consequent prolonged need for parenteral nutrition can have serious infectious and metabolic
complications, which might prolong hospital stay, increase morbidity and mortality, and affect growth
and development [4].
Several clinical variables and interventions have been proposed as predictors of the time to FEF
achievement in preterm and very-low-birth-weight (VLBW) infants. Among these variables, the
influence of type of feeding was also documented, as FEF achievement was delayed in formula-fed
infants compared to human milk (HM)-fed infants [5].
Recently, probiotic use has been associated with a reduced time to achieve FEF and better
feeding tolerance [6], as well as a reduction of NEC [7,8] and late-onset sepsis [9]. Probiotics are
live microorganisms which, when ingested in adequate amounts, confer a health benefit to the host,
by modifying the composition and function of gut microbiota and the immunological responses in
the host [10]. The role of probiotics in attaining a more rapid achievement of FEF could be related
to their favorable effect on the physiological intestinal dysbiosis of preterm infants [11], which is the
result of the exposure to a unique environment and to several iatrogenic manipulations, such as broad
spectrum antibiotics [12]. It is well known that gut microbiota in HM-fed infants is different compared
to formula-fed infants [13]; data from an observational study also suggest a feeding-dependent effect of
probiotics, as in that study NEC incidence was reduced in infants treated with probiotics and receiving
HM, but not in those exclusively formula-fed [14]. However, the relationship between probiotics and
type of feeding in attaining a more rapid achievement of FEF has not been explored yet, even in the
most recent meta-analysis on this topic [6].
Thus, the aim of the present paper was to evaluate the effect of probiotics on time to FEF
achievement according to type of feeding (exclusive HM vs. formula), by performing a systematic
review and meta-analysis of currently available literature on this topic.
2. Materials and Methods
2.1. Literature Search
The study protocol was designed by the members of the Task Force on Probiotics of the Italian
Society of Neonatology. PRISMA guidelines [15] were followed in order to perform a systematic review
of published studies reporting the relationship between probiotic use and time to FEF achievement in
preterm infants according to type of feeding.
In order to be included in the meta-analysis, studies had to meet the following inclusion
criteria: randomized or quasi-randomized clinical trials involving preterm infants (gestational age
(GA) <37 weeks) who received, within one month of age, any probiotic compared to placebo or no
treatment, and reporting on type of feeding. The outcome of interest was time for FEF achievement
(any definition). Only English-written studies and studies involving humans were included in the
meta-analysis.
A search was conducted for studies published before 2 March 2016 in PubMed [16], the Cochrane
Library [17], and Embase [18]. The following search string was used for the PubMed search: ((preterm
infant OR pre-term infant) OR (preterm infants OR pre-term infants) OR (preterm neonate OR pre-term
neonate) OR (preterm neonates OR pre-term neonates) OR (preterm newborn OR pre-term newborn)
OR (preterm newborns OR pre-term newborns) OR (premature infant OR premature infants) OR
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(premature neonate OR premature neonates) OR (premature newborn OR premature newborns) OR
infant, extremely premature (MeSH Heading (MH)) OR premature birth (MH) OR infant, low birth
weight (MH) OR infant, very low birth weight (MH)) AND (full enteral* OR feed*) AND (probiotic OR
probiotics OR pro-biotic OR pro-biotics OR probio*)) NOT (animals (MH) NOT humans (MH).
The string was built up by combining all the terms related to probiotics and FEF achievement:
PubMed MeSH terms, free-text words, and their combinations obtained through the most proper
Boolean operators were used. The same criteria were used for searching the Cochrane Library
and Embase.
Arianna Aceti and Luigi Corvaglia performed the literature search: relevant studies were
identified from the abstract; full-texts of relevant studies were examined, as well as their reference lists
in order to identify additional studies.
2.2. Data Extraction and Meta-Analysis
Study details (population, characteristics of probiotic and placebo, type of feeding, and outcome
assessment) were evaluated independently by Arianna Aceti and Luigi Corvaglia, and checked by
Davide Gori. Study quality was evaluated independently by Arianna Aceti and Davide Gori using the
risk of bias tool as proposed by the Cochrane collaboration (Chapter 8 of the Cochrane Handbook of
Systematic Reviews) [19].
The corresponding authors of the studies in which days to FEF achievement were not reported as
mean ˘ standard deviation (SD) were contacted by email. When data were not provided, the study
was not included in the meta-analysis.
The association between probiotic use and FEF achievement according to type of feeding was
evaluated by a meta-analysis conducted by AA and DG using the RevMan software (Cochrane
Informatics and Knowledge Management Department, version 5.3.5) downloaded from the Cochrane
website [20]. Mean difference (MD) in days to achieve FEF between infants receiving probiotics
and those receiving placebo or no treatment was calculated using the inverse variance method, and
reported with 95% confidence interval (CI).
For the analysis, we planned to use at first a fixed effect model. Heterogeneity was measured
using the I2 test: if significant heterogeneity was present (p < 0.05 from the χ2 test) and/or the number
of studies was ď5, a random-effects model was used instead.
3. Results
Literature Search
Overall, 372 papers were identified through the literature search, 155 in PubMed [16], 73 in the
Cochrane Library [17], and 144 in Embase [18].
As shown in Figure 1, 35 studies met the inclusion criteria [21–55]. Fourteen additional papers
were identified from the reference lists of included studies or by “snowballing” techniques [52,56–68].
Twenty-four studies were excluded after examining the full-texts [28,29,31–33,35,42–47,51,53–
55,57–59,62,63,65,69]. Twenty-five studies were then suitable for inclusion in the systematic review
(Table 1) [21–27,30,34,36–41,48–50,56,60,61,64,66,68,70].
Among them, only eight studies reported FEF achievement according to type of feeding:
infants were fed exclusively HM, either own mother’s (OMM) or donor human milk (DHM), in six
studies [22,38,50,56,60,70], while two studies reported FEF in exclusively formula-fed infants [41,61].
The corresponding authors of four of these papers were contacted by email, as data for FEF
achievement were not suitable for inclusion in the meta-analysis: mean ˘ SD of days for FEF
achievement were provided for one study [22], while data were unavailable for three studies [41,61,70];
these three studies were thus excluded from the meta-analysis.
Overall, five studies were included in the meta-analysis: in all these studies, infants were fed
exclusively HM, either OMM or DHM (Figure 1) [22,38,50,56,60].
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Table 1. Studies included in the systematic review.
Author, Year Study Details Study Population
Intervention Specie
Milk Placebo FEF Definition
Dose (D)
Start of Treatment (S)
End of Treatment (E)
Bin-Nun, 2005 [40]
P
Preterm infants with BW < 1500 g, who
began enteral feeding on a weekday
B. infantis, Str. thermophilus, B. bifidus
OMM, PFM HM or FM 100 mL/kg/day
B D: 0.35 ˆ 109 CFU each, OD
R S: start of enteral feeding
C E: 36 w postconceptual age
Braga, 2011 [60]
P
Inborn infants with BW 750–1499 g
L. casei, B. Breve
HM (˘ PFM from w3) Extra HM 150 mL/kg/day
DB D: 3.5 ˆ 107 CFU to 3.5 ˆ 109 CFU OD
R S: day 2
C E: day 30, NEC diagnosis, discharge, death,whichever occurred first
Costalos, 2003 [41]
P GA 28–32 w Saccharomyces boulardii
PFM MDX Not defined
R No major GI problem D: 1 ˆ 109 CFU BD
C Not receiving antibiotics S: non-specified
Not receiving breast milk Median duration of probiotic supplementation:30 days
Costeloe, 2015 [64]
P
Preterm infants with
GA 23–30 + 6 weeks, without any lethal
malformation or any malformation of
the GI tract
Bifidobacterium breve BBG-001
OMM, DHM, FM Corn starch powder 150 mL/kg/day
DB D: 8 ¨ 3–8 ¨ 8 log10 CFU/day
R S: as soon as possible after randomisation
C E: 36 w PMA or discharge if sooner
Multic.
Demirel, 2013 [27]
P
Preterm infants with GA ď 32 weeks
and BW ď 1500 g, who survived to
feed enterally
S. boulardii
HM, FM None Not defined
B D: 5 ˆ 109 CFU OD
R S: first feed
C E: discharge
Dilli, 2015 [49]
P
Preterm infants with GA < 32 weeks and
BW < 1500 g, born at or transferred to
the NICU within the first week of life
and fed enterally before inclusion
B. lactis
HM, FM MDX powder
100 mL/kg/day
(FEF for hydration)
DB D: 5 ˆ 109 CFU 150 mL/kg/day(FEF for growth)
R S: beyond d7 after birth
C E: death or discharge (max 8 weeks)
Multic.
Nutrients 2016, 8, 471 6 of 16
Table 1. Cont.
Author, Year Study Details Study Population
Intervention Specie
Milk Placebo FEF Definition
Dose (D)
Start of Treatment (S)
End of Treatment (E)
Fernández-Carrocera,
2013 [30]
P Preterm infants with
L. acidophilus 1 ˆ 109 CFU/g, L. rhamnosus
4.4 ˆ 108 CFU/g, L. casei 1 ˆ 109 CFU/g,
L. plantarum 1.76 ˆ 108 CFU/g, B. infantis
2.76 ˆ 107 CFU/g, Str. thermophilus
6.6 ˆ 105 CFU/g OMM, PFM None Not defined
DB BW < 1500 g Total D: 1 g powder OD
R Infants with NEC stage IA and stage IBwere excluded S: start of enteral feeding
C E: non specified
Hays, 2014 [66]
P
Preterm infants with GA 25–31 weeks,
BW 700–1600 g, AGA, enteral feeding
initiated before day 5
Probiotic group composed of 3 subgroups:
OMM, DM or PFM MDX Not defined
DB
Infants with NEC stage ě IB,
malformations or severe medical or
surgical conditions were excluded
P1 B. lactis
R P2 B. longum
C P3 B. lactis + longum
Multic.
D: 1 ˆ 109 CFU each probiotic daily
Duration: 4 weeks for infants ě29 w/6 weeks for
infants ď28 w GA
Hikaru, 2010 [68]
P
Extremely low birth weight and very
low birth weight infants
B. breve
OMM, PFM None Not defined
R D: 0.5 ˆ 109 CFU BD
C S: birth
E: discharge from NICU
Jacobs, 2013 [25]
P
Preterm infants with GA <32 weeks and
BW < 1500 g
B. infantis BB-02 300 CFU ˆ 106, Str. thermophilus
Th-4 350 CFU ˆ 106, B. lactis BB-12 350 CFU ˆ 106
HM, FM MDX powder
Enteral feeds of
120 mL/kg for
ě3 days
DB Total D: 1 ˆ 109 CFU ˆ 1.5 g MDX powder OD
R S: enteral feed ě 1 mL every 4 h
C E: discharge or term corrected age
Multic.
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Table 1. Cont.
Author, Year Study Details Study Population
Intervention Specie
Milk Placebo FEF Definition
Dose (D)
Start of Treatment (S)
End of Treatment (E)
Lin, 2008 [39]
P
Preterm infants with GA < 34 weeks and
BW ď 1500 g, who survived to feed
enterally
L. acidophilus NCDO 1746, B. bifidum
NCDO 1453 109 CFU
HM, FM None
Oral intake of
100 mL/kg/day
B D: 1 ˆ 109 CFU each probiotic (= 125 mg/kg) BD
R S: day 2 of age
C Duration: 6 weeks
Multic.
Manzoni, 2006 [56]
P
Infants with BW < 1500 g, ě3 day of life,
who started enteral feeding with HM
L. casei subspecies rhamnosus LGG
OMM, DM None Not defined
DB D: 6 ˆ 109 CFU/day
R S: day 3 of life
C E: end of the 6th week or discharge
Mihatsch, 2010 [36]
P
Preterm infants with GA < 30 weeks and
BW ď 1500 g
B. lactis BB12
OMM, PFM
Indistinguishable
powder
150 mL/kg/day
R D: 2 ˆ 109 CFU/kg 6 times a day
C S: start of enteral feeding
E: non specified
Oncel, 2014 [24]
P
Preterm infants with GA ď 32 weeks
and BW ď 1500 g, who survived to
feed enterally
L. reuteri DSM 17938
HM, FM Oil base Not defined
DB D: 1 ˆ 108 CFU OD
R S: first feed
C E: death or discharge
Patole, 2014 [23]
P
Preterm infants with GA < 33 weeks and
BW < 1500 g
B. breve
HM, FM Dextrin
150 mL/kg/day
enteral feeding
DB
D: 3 ˆ 109 CFU OD (1.5 ˆ 109 CFU OD for
newborn ď 27 w until they reached
50 mL/kg/day enteral feeds)
R S: start of enteral feed
C E: corrected age of 37 w
Rougé, 2009 [37]
P
Preterm infants with GA < 32 weeks and
BW < 1500 g, ď2 weeks of age, without
any disease other than those linked to
prematurity, who started enteral feeding
before inclusion
B. longum BB536, L. rhamnosus GG BB536-LGG
OMM, DM or PFM MDX Not defined
DB Total D: 1 ˆ 108 CFU/day
R S: start of enteral feeding
C E: discharge
Bic.
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Table 1. Cont.
Author, Year Study Details Study Population
Intervention Specie
Milk Placebo FEF Definition
Dose (D)
Start of Treatment (S)
End of Treatment (E)
Roy, 2014 [50]
P
Preterm infants (GA < 37 weeks) and
BW < 2500 g, with stable enteral feeding
within 72 h of birth
L. acidophilus 1.25 ˆ 109 CFU ˆ 1 g, B. longum
0.125 ˆ 109 CFU ˆ 1 g, B. bifidum
0.125 ˆ 109 CFU ˆ 1 g, B. lactis 1ˆ 109 CFUˆ 1 g
HM Sterile water
120 mL/kg/day
for ě3 dDB D: half a 1 g sachet
R S: from 72 h of life
C E: after 6 w or at discharge
Saengtawesin,
2014 [48]
P
Preterm infants with GA ď 34 weeks
and BW ď 1500 g
L. acidophilus 1 ˆ 109 CFU, B. bifidum 1 ˆ 109 CFU
HM, PFM None 150 mL/kg/day
R D: 125 mg/kg BD
C S: start of feeding
E: 6 w of age or discharge.
Samanta, 2008 [38]
P
Preterm infants with GA < 32 weeks and
BW < 1500 g, who started enteral
feeding and survived beyond 48 h of age
B. infantis, B. bifidum, B. longum, L. acidophilus
HM None Not defined
DB
R D: 2.5 ˆ 109 CFU each probiotic, BD
C S: start of enteral feeding
E: discharge
Sari, 2011 [34]
P
Preterm infants with GA < 32 weeks or
BW < 1500 g, who survived to feed
enterally
L. sporogenes
HM, FM None Not defined
B D: 0.35 ˆ 109 CFU OD
R S: first feed
C E: discharge
Serce, 2013 [26]
P
Preterm infants with GA ď 32 weeks
and BW ď 1500 g, who survived to
feed enterally
S. boulardii
HM, FM Distilled water
100 mL/kg/day
M D: 0.5 ˆ 109 CFU/kg BD enteral feeding
R S: non specified
C E: non specified
Stratiki, 2007 [61]
P
Preterm infants with GA 27–32 weeks,
formula-fed, without major
congenital anomalies
Bifidobacterium lactis
FM None 150 mL/kg/day
B D: 2 ˆ 107 CFU/g of milk powder
R S: start of enteral feeding
C E: not specified
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Table 1. Cont.
Author, Year Study Details Study Population
Intervention Specie
Milk Placebo FEF Definition
Dose (D)
Start of Treatment (S)
End of Treatment (E)
Tewari, 2015 [70]
P Preterm infants with GA < 34 weeks Bacillus clausii
OMM, DHM Sterile water 180 mL/kg/day
DB Excluded if: NEC, congenital anomaly ,outborn and >10 days of with sepsis D: 2.4 ˆ 10
9 CFU/day
R
Stratified as extreme preterm
(GA 27–30 + 6) and very preterm
(GA 31–33 + 6)
S: by day 5 in asymptomatic and by day 10 in
symptomatic infants
C E: 6 weeks of age, discharge or death (whicheveroccurred first)
Totsu, 2014 [21]
P
Infants with BW < 1500 g
B. bifidum
HM, FM Dextrin
Postnatal day at
which the amount of
enteral feeding
exceeded
100 mL/kg/day
DB D: 2.5 ˆ 109 CFU, divided in two doses
CLR S: within 48 h after birth
C E: body weight 2000 g
Multic.
Van Niekerk,
2014 [22]
P Preterm infants with GA < 34 weeks and
BW < 1250 g, exposed and non-exposed
to HIV (only infants unexposed to HIV
are included in the meta-analysis)
L. rhamnosus, B. infantis
HM MCT oil
“when infants no
longer required the
use of IV fluids”
DB D: 0.35 ˆ 109 CFU each probiotic
R S: start of enteral feeding
C E: day 28 postconceptual age
P: prospective; B: blinded; R: randomized; C: controlled; DB: double-blinded; Multic: multicentric; M: masked; CLR: cluster-randomized; BW: birth weight; GA: gestational age;
HM: human milk; L.: Lactobacillus; B.: Bifidobacterium; Str.: Streptococcus; S.: Saccharomyces; CFU: colony forming unit; OD: once daily; NEC: necrotizing enterocolitis; BD: twice
daily; OMM: own mother’s milk; PFM: preterm formula; FM: formula; MDX: maltodextrin; PMA: postmenstrual age; AGA: appropriate for gestational age.
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Data from 359 infants in the probiotic group and 360 infants in the control group were evaluated:
probiotic use was associated with a reduction in the time for FEF achievement (MD´3.15 days (95% CI
´5.25/´1.05), p = 0.003; Figure 2a). The funnel plot did not show any clear asymmetry (Figure 2b).
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0.004). 
4. Methodological Study Quality 
- . :
i t .
Three studies were not included in the meta-analysis because data on FEF were not available as
mean˘ SD [41,61,70]. One study reported the use of Bacillus clausii in preterm infants with GA < 34 weeks,
fed expressed breast milk or DHM [70] and stratified as extreme preterm (GA 27–30 + 6 weeks) and
very preterm (GA 31–33 + 6 weeks). In both groups, probiotic use was associated with a reduced time
to achieve FEF (risk ratio 0.82 (95% CI 0.74–0.88) and 0.67 (95% CI 0.32–0.77), respectively).
The other two studies reported probiotic use in exclusively formula-fed infants: in the study by
Costalos et al., infants born at 28–32 weeks gestation and fed exclusively preterm formula received
Saccharomyces boulardii or placebo for approximately 30 days [41]. In the study by Stratiki et al.,
formula-fed infants with a similar gestational age (27–32 weeks) received Bifidobacterium lactis vs. no
treatment [61]. Neither of these two studies reported any significant difference between groups in
terms of time to FEF achievement.
All the studies included in the meta-analysis, except one [50], recruited exclusively infants with
birth weight <1500 g. The study by Roy et al. [50] reported specific data for extremely low birth weight
(ELBW) infants: time to reach FEF in ELBW infants treated with probiotics was significantly lower
than in controls (mean ˘ SD 13.22 ˘ 5.04 vs. 17.41 ˘ 8.07, respectively, p = 0.014). None of the studies
included in the meta-analysis reported separate data on intrauterine growth restricted (IUGR) infants.
In all the studies, except one [56], a probiotic mix was used: the meta-analysis performed after
the exclusion of the study by Manzoni et al., where a single-strain product containing Lactobacillus
GG was used, confirmed the results of the overall analysis (MD ´3.33 days (95% CI ´5.63/´1.04),
p ď 0.004).
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4. Methodological Study Quality
Evaluation of the quality of the studies included in the meta-analysis according to the risk of bias
tool as proposed by the Cochrane Collaboration [19] is shown in Table 2.
Table 2. Evaluation of the quality of the studies included in the meta-analysis according to the risk of
bias tool as proposed by the Cochrane collaboration.
Study Random SequenceGeneration
Allocation
Concealment Blinding
Incomplete
Outcome Data
Selective Outcome
Reporting
Other Sources
of Bias
Braga, 2011 [60] Low Low Low Low Unclear Low
Manzoni, 2006 [56] Low Low Low Unclear Unclear Low
Roy, 2014 [50] Low Unclear Low Low Unclear Unclear
Samanta, 2008 [38] Low Low Low Unclear Unclear Unclear
Van Niekerk, 2014 [22] Low Unclear Low Unclear Unclear Unclear
5. Discussion
The present meta-analysis shows that the use of probiotics in preterm, VLBW infants fed
exclusively HM is associated with 3-days reduction in the time to FEF achievement. The only two
studies included in the present systematic review in which infants were exclusively formula-fed did
not report any difference between the probiotic and the control group.
The single previous meta-analysis investigating FEF as primary outcome showed an overall
smaller reduction in the time to FEF achievement, but did not report separate data for HM-fed and
formula-fed infants [6]. The studies included in the meta-analysis by Athalye-Jape et al. are almost
the same as those included in our systematic review; quite surprisingly, in the majority of the studies
included in these two reviews, both HM and formula-fed infants were recruited, but no detailed
information on the relationship between type of feeding and outcome was provided.
Type of feeding might modulate the relationship between probiotics and neonatal clinical
outcome [14]. It has been previously shown that HM feeding is associated with shorter time to
achieve FEF compared to formula feeding [5]. Our meta-analysis, which included only studies where
infants were exclusively HM-fed, showed a significant reduction in the time to achieve FEF attributable
to probiotics. Despite the limitation given by the small number of studies, a probiotic-related 3-days
reduction in time to achieve FEF in preterm infants fed exclusively HM has strong clinical implications
and deserves further consideration. When OMM is not available or contraindicated, the use of
pasteurized DHM is recommended for preterm infants: pasteurization inactivates most viral and
bacterial agents, but at the same time affects some nutritional and immunological properties of HM,
including endogenous probiotics [71]. It can be speculated that the beneficial effect of probiotics
documented in exclusively HM-fed infants could be attributed to a synergic action exerted by the
prebiotic components of HM and the exogenous probiotic, which partially restores the symbiotic
properties of naïve HM [72]. In the present meta-analysis, no separate data for OMM-fed and DHM-fed
infants were available; for this reason, it is not possible to clarify whether the beneficial effect of HM
on FEF achievement applies both to OMM and to DHM.
Heterogeneity among included studies was high; however, given the small number of papers, our
ability to explore sources of heterogeneity was limited. In the five included studies, different probiotic
strains were used. We aimed to perform strain-specific sub-meta-analyses, in order to clarify whether
there was any probiotic product showing a significant benefit in terms of reduction in the time to
achieve FEF. However, such analyses were not feasible, as none of the studies used the same probiotic
strain or mix. Similarly, it was not possible to explore additional sources of heterogeneity, such as
the characteristics of probiotic administration (dose, duration, infant age at probiotic initiation, etc.).
In addition, we were unable to test for subgroup differences between HM-fed and formula-fed infants,
which might have partially explained the different results in terms of FEF achievement.
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Apparently, studies were homogeneous in terms of included populations, as almost all of them
recruited only VLBW infants. However, few data on “high-risk” infants, such as ELBW and IUGR
infants, could be extrapolated from the main results of the included studies.
The use of probiotics should be weighed against their potential side effects. There are some reports
about the occurrence of sepsis in preterm newborns, potentially linked to probiotic administration [73].
However, none of the studies included in the systematic review reported any side effect related to
the use of probiotics.
6. Conclusions
According to the results of the present meta-analysis, the use of probiotics is linked to 3-days
reduction in time to achieve FEF in preterm VLBW infants fed exclusively HM. If confirmed in further
studies, this reduction might have strong clinical implications for this high-risk population.
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